Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

PHASE4CompletedINTERVENTIONAL
Enrollment

595

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

February 29, 2004

Conditions
Coronary ArteriosclerosisDiabetes Mellitus, Type 2Cerebrovascular AccidentDyslipidemiaPeripheral Vascular Disease
Interventions
DRUG

Atorvastatin (Lipitor)

Trial Locations (32)

Unknown

Pfizer Investigational Site, Ioannina

Pfizer Investigational Site, Kallithea, Athens

Pfizer Investigational Site, Pireaus

Pfizer Investigational Site, Thessaloniki

Pfizer Investigational Site, Budapest

Pfizer Investigational Site, Gyula

Pfizer Investigational Site, Kecskemét

Pfizer Investigational Site, Nyíregyháza

Pfizer Investigational Site, Szekszárd

Pfizer Investigational Site, Tullamore

Pfizer Investigational Site, Tallaght

Pfizer Investigational Site, Gorey

Pfizer Investigational Site, Cork

Pfizer Investigational Site, Dublin

Pfizer Investigational Site, Galway

Pfizer Investigational Site, Częstochowa

Pfizer Investigational Site, Poznan

Pfizer Investigational Site, Warsaw

Pfizer Investigational Site, Wroclaw

Pfizer Investigational Site, Zabrze

Pfizer Investigational Site, Aveiro

Pfizer Investigational Site, Lisbon

Pfizer Investigational Site, Porto

Pfizer Investigational Site, Vila Franca de Xira

Pfizer Investigational Site, Moscow

Pfizer Investigational Site, Bratislava

Pfizer Investigational Site, Košice

Pfizer Investigational Site, Bern

Pfizer Investigational Site, Geneva

Pfizer Investigational Site, Mendrisio

Pfizer Investigational Site, Zurich

Pfizer Investigational Site

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00442325 - Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets | Biotech Hunter | Biotech Hunter